top of page

Melius receives Australian OGTR DIR licence to support first-in-human clinical trial of MMB-003

  • Mar 17
  • 1 min read

Melius MicroBiomics has received a DIR (Dealings Involving Intentional Release) licence from Australia's OGTR (Office of the Gene Technology Regulator), marking a key regulatory milestone as the company advances toward its first-in-human clinical trial in Australia.




The DIR licence supports the planned clinical evaluation of MMB-003 (EcN::ttr), an investigational engineered microbial therapeutic being developed as a potential treatment for ulcerative colitis.


This milestone represents an important step forward in the development of Melius' microbiome-based therapeutics aimed at addressing unmet medical needs.


Read full press release:


View the OGTR licence: DIR 221



About Us

Melius MicroBiomics is a biotechnology company developing next-generation engineered live microbial products designed to improve human and animal health. Built on patented genetic engineering platforms and deep expertise in microbial ecosystems, Melius augments the natural healing properties of beneficial bacteria by enabling them to thrive under inflammatory conditions characteristic of many chronic diseases.


Melius is currently preparing for a first-in-human clinical trial of its lead candidate, MMB-003 (EcN::ttr), being developed as a potential therapy for ulcerative colitis.


For more information, please visit https://www.mmblivebio.com and follow us on LinkedIn


Melius Media Contact:

Leah D'Aloisio

Medical Science Writer

Melius MicroBiomics, ldaloisio@mmblivebio.com 

 

 
 
bottom of page